Enterobacteriaceae are a large family of different types of germs (bacteria) that commonly cause infections in healthcare settings. Examples of germs in the Enterobacteriaceae family include Escherichia coli (E. coli) and Klebsiella pneumoniae.
MARKET DYNAMICS
Rising prevalence of Enterobacteriaceae infectious diseases, For instance, in 2020, CRE caused an estimated 13,100 infections in hospitalized patients, and 1,100 estimated deaths in the United States increasing modes of spread of the infectious disease and a lack of cleanliness are the driving factors. However, the major factor which will restrain the market growth rapid resistance to drugs currently available for enterobacter infections. Furthermore, launch of new antibiotics with activity against carbapenem-resistant Enterobacteriaceae (CRE) will offer lucrative opportunities in the market.
MARKET SCOPE
`
The "Global Enterobacteriaceae Infection Drug Market analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Enterobacteriaceae Infection Drug Market with detailed market segmentation by type, distribution channel, and geography. The Global Enterobacteriaceae Infection Drug Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Enterobacteriaceae Infection Drug Market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Global Enterobacteriaceae Infection Drug Market is segmented on the basis of type and distribution channel. On the basis of type, market can be classified as beta-lactams drugs, carbapenems drugs, fluoroquinolones drugs, others. On the basis of distribution channel the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies
. ?
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Enterobacteriaceae Infection Drug Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Enterobacteriaceae Infection Drug Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Enterobacteriaceae Infection Drug Market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Enterobacteriaceae Infection Drug Market in these regions.
Have a question?
Akshay
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Enterobacteriaceae Infection Drug Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Enterobacteriaceae Infection Drug Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Enterobacteriaceae Infection Drug Market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Enterobacteriaceae Infection Drug Market in these regions.
MARKET PLAYERS
The report covers key developments in the Enterobacteriaceae Infection Drug Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Enterobacteriaceae Infection Drug Market are anticipated to lucrative growth opportunities in the future with the rising demand for Enterobacteriaceae Infection Drug Market in the global market. Below mentioned is the list of few companies engaged in the Enterobacteriaceae Infection Drug Market.
The report also includes the profiles of key Enterobacteriaceae Infection Drug Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Genentech, Inc.
- Allergan
- Novartis AG
- Pfizer Inc.
- Nymox Pharmaceutical Corporation
- Sequoia Sciences, Inc.
- Phico Therapeutics Ltd.
- Melinta Therapeutics, Inc.
- Spero Therapeutics
- Cipla USA, Inc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Enterobacteriaceae Infection Drug - By Type
1.3.2 Enterobacteriaceae Infection Drug - By Distribution Channel
1.3.3 Enterobacteriaceae Infection Drug - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ENTEROBACTERIACEAE INFECTION DRUG LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ENTEROBACTERIACEAE INFECTION DRUG - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. ENTEROBACTERIACEAE INFECTION DRUG - GLOBAL MARKET ANALYSIS
6.1. ENTEROBACTERIACEAE INFECTION DRUG - GLOBAL MARKET OVERVIEW
6.2. ENTEROBACTERIACEAE INFECTION DRUG - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ENTEROBACTERIACEAE INFECTION DRUG - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. BETA-LACTAMS DRUGS
7.3.1. Overview
7.3.2. Beta-Lactams Drugs Market Forecast and Analysis
7.4. CARBAPENEMS DRUGS
7.4.1. Overview
7.4.2. Carbapenems Drugs Market Forecast and Analysis
7.5. FLUOROQUINOLONES DRUGS
7.5.1. Overview
7.5.2. Fluoroquinolones Drugs Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. ENTEROBACTERIACEAE INFECTION DRUG - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. ENTEROBACTERIACEAE INFECTION DRUG REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Enterobacteriaceae Infection Drug Overview
9.1.2 North America Enterobacteriaceae Infection Drug Forecasts and Analysis
9.1.3 North America Enterobacteriaceae Infection Drug Forecasts and Analysis - By Type
9.1.4 North America Enterobacteriaceae Infection Drug Forecasts and Analysis - By Distribution Channel
9.1.5 North America Enterobacteriaceae Infection Drug Forecasts and Analysis - By Countries
9.1.5.1 United States Enterobacteriaceae Infection Drug
9.1.5.1.1 United States Enterobacteriaceae Infection Drug by Type
9.1.5.1.2 United States Enterobacteriaceae Infection Drug by Distribution Channel
9.1.5.2 Canada Enterobacteriaceae Infection Drug
9.1.5.2.1 Canada Enterobacteriaceae Infection Drug by Type
9.1.5.2.2 Canada Enterobacteriaceae Infection Drug by Distribution Channel
9.2. EUROPE
9.2.1 Europe Enterobacteriaceae Infection Drug Overview
9.2.2 Europe Enterobacteriaceae Infection Drug Forecasts and Analysis
9.2.3 Europe Enterobacteriaceae Infection Drug Forecasts and Analysis - By Type
9.2.4 Europe Enterobacteriaceae Infection Drug Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Enterobacteriaceae Infection Drug Forecasts and Analysis - By Countries
9.2.5.1 Germany Enterobacteriaceae Infection Drug
9.2.5.1.1 Germany Enterobacteriaceae Infection Drug by Type
9.2.5.1.2 Germany Enterobacteriaceae Infection Drug by Distribution Channel
9.2.5.2 France Enterobacteriaceae Infection Drug
9.2.5.2.1 France Enterobacteriaceae Infection Drug by Type
9.2.5.2.2 France Enterobacteriaceae Infection Drug by Distribution Channel
9.2.5.3 Italy Enterobacteriaceae Infection Drug
9.2.5.3.1 Italy Enterobacteriaceae Infection Drug by Type
9.2.5.3.2 Italy Enterobacteriaceae Infection Drug by Distribution Channel
9.2.5.4 Spain Enterobacteriaceae Infection Drug
9.2.5.4.1 Spain Enterobacteriaceae Infection Drug by Type
9.2.5.4.2 Spain Enterobacteriaceae Infection Drug by Distribution Channel
9.2.5.5 United Kingdom Enterobacteriaceae Infection Drug
9.2.5.5.1 United Kingdom Enterobacteriaceae Infection Drug by Type
9.2.5.5.2 United Kingdom Enterobacteriaceae Infection Drug by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Enterobacteriaceae Infection Drug Overview
9.3.2 Asia-Pacific Enterobacteriaceae Infection Drug Forecasts and Analysis
9.3.3 Asia-Pacific Enterobacteriaceae Infection Drug Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Enterobacteriaceae Infection Drug Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Enterobacteriaceae Infection Drug Forecasts and Analysis - By Countries
9.3.5.1 Australia Enterobacteriaceae Infection Drug
9.3.5.1.1 Australia Enterobacteriaceae Infection Drug by Type
9.3.5.1.2 Australia Enterobacteriaceae Infection Drug by Distribution Channel
9.3.5.2 China Enterobacteriaceae Infection Drug
9.3.5.2.1 China Enterobacteriaceae Infection Drug by Type
9.3.5.2.2 China Enterobacteriaceae Infection Drug by Distribution Channel
9.3.5.3 India Enterobacteriaceae Infection Drug
9.3.5.3.1 India Enterobacteriaceae Infection Drug by Type
9.3.5.3.2 India Enterobacteriaceae Infection Drug by Distribution Channel
9.3.5.4 Japan Enterobacteriaceae Infection Drug
9.3.5.4.1 Japan Enterobacteriaceae Infection Drug by Type
9.3.5.4.2 Japan Enterobacteriaceae Infection Drug by Distribution Channel
9.3.5.5 South Korea Enterobacteriaceae Infection Drug
9.3.5.5.1 South Korea Enterobacteriaceae Infection Drug by Type
9.3.5.5.2 South Korea Enterobacteriaceae Infection Drug by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Enterobacteriaceae Infection Drug Overview
9.4.2 Middle East and Africa Enterobacteriaceae Infection Drug Forecasts and Analysis
9.4.3 Middle East and Africa Enterobacteriaceae Infection Drug Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Enterobacteriaceae Infection Drug Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Enterobacteriaceae Infection Drug Forecasts and Analysis - By Countries
9.4.5.1 South Africa Enterobacteriaceae Infection Drug
9.4.5.1.1 South Africa Enterobacteriaceae Infection Drug by Type
9.4.5.1.2 South Africa Enterobacteriaceae Infection Drug by Distribution Channel
9.4.5.2 Saudi Arabia Enterobacteriaceae Infection Drug
9.4.5.2.1 Saudi Arabia Enterobacteriaceae Infection Drug by Type
9.4.5.2.2 Saudi Arabia Enterobacteriaceae Infection Drug by Distribution Channel
9.4.5.3 U.A.E Enterobacteriaceae Infection Drug
9.4.5.3.1 U.A.E Enterobacteriaceae Infection Drug by Type
9.4.5.3.2 U.A.E Enterobacteriaceae Infection Drug by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Enterobacteriaceae Infection Drug Overview
9.5.2 South and Central America Enterobacteriaceae Infection Drug Forecasts and Analysis
9.5.3 South and Central America Enterobacteriaceae Infection Drug Forecasts and Analysis - By Type
9.5.4 South and Central America Enterobacteriaceae Infection Drug Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Enterobacteriaceae Infection Drug Forecasts and Analysis - By Countries
9.5.5.1 Brazil Enterobacteriaceae Infection Drug
9.5.5.1.1 Brazil Enterobacteriaceae Infection Drug by Type
9.5.5.1.2 Brazil Enterobacteriaceae Infection Drug by Distribution Channel
9.5.5.2 Argentina Enterobacteriaceae Infection Drug
9.5.5.2.1 Argentina Enterobacteriaceae Infection Drug by Type
9.5.5.2.2 Argentina Enterobacteriaceae Infection Drug by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ENTEROBACTERIACEAE INFECTION DRUG, KEY COMPANY PROFILES
11.1. GENENTECH, INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ALLERGAN
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. NOVARTIS AG
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. PFIZER INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. NYMOX PHARMACEUTICAL CORPORATION
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. SEQUOIA SCIENCES, INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. PHICO THERAPEUTICS LTD.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. MELINTA THERAPEUTICS, INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. SPERO THERAPEUTICS
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. CIPLA USA, INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. Genentech, Inc.
2. Allergan
3. Novartis AG
4. Pfizer Inc.
5. Nymox Pharmaceutical Corporation
6. Sequoia Sciences, Inc.
7. Phico Therapeutics Ltd.
8. Melinta Therapeutics, Inc.
9. Spero Therapeutics
10. Cipla USA, Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Enterobacteriaceae Infection Drug Market
Apr 2024
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2024
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Apr 2024
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Apr 2024
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2024
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2024
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Apr 2024
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Apr 2024
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)